Skip to main content
Clinical Trials/NCT01608230
NCT01608230
Completed
N/A

Human Tumor Sequencing Project

Scripps Translational Science Institute1 site in 1 country35 target enrollmentApril 2010
ConditionsCancer

Overview

Phase
N/A
Intervention
Not specified
Conditions
Cancer
Sponsor
Scripps Translational Science Institute
Enrollment
35
Locations
1
Primary Endpoint
Determine biomarkers of clinical utility and copy number variants through genetic analysis.
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

This study is being done to learn more about genetic mutations in cancer cells and to find out how the development of new technologies can increase knowledge of these mutations and possibly predict an individual's response to certain treatments.

Registry
clinicaltrials.gov
Start Date
April 2010
End Date
April 2014
Last Updated
11 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Scripps Translational Science Institute
Responsible Party
Principal Investigator
Principal Investigator

Eric Topol, MD

Director

Scripps Translational Science Institute

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of a solid tumor or blood borne cancer
  • 18 years or older
  • Eligible to have blood drawn

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Determine biomarkers of clinical utility and copy number variants through genetic analysis.

Time Frame: four years

Study Sites (1)

Loading locations...

Similar Trials